Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
Peter Orth, Alex G. Therien(Merck Canada Inc. (Canada)), Edward DiNunzio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Grigori Ermakov(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fred Racine(Merck & Co., Inc., Rahway, NJ, USA (United States)), Le Xiao(Hainan Medical University), Todd Mayhood(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jerzy Karczewski, Lorraine D. Hernandez(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard Ingram(Merck & Co., Inc., Rahway, NJ, USA (United States)), P Reichert, Maribel Beaumont(Merck & Co., Inc., Rahway, NJ, USA (United States)), Corey Strickland(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Payal R. Sheth(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susan Secore(United States Military Academy)
Cited by 0
Related Papers
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation
|Biochemical Journal|2006|272